Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

All Trilipix Options Available To Advisory Committee

This article was originally published in The Pink Sheet Daily

Executive Summary

ACCORD-Lipid trial results could lead members to recommend conducting another trial, revising the label, withdrawing the indication or take no action for Trilipix coadministration with a statin.
Advertisement

Related Content

Trilipix Use In Diabetics Might Be Restricted After FDA Panel Review Of ACCORD Data
Trilipix Use In Diabetics Might Be Restricted After FDA Panel Review Of ACCORD Data
Abbott/AstraZeneca's Certriad Bounced By FDA; ACCORD May Be The Culprit
Abbott's Fibrate Franchise Will Likely Remain Limited To High-Risk Patients After ACCORD

Topics

Advertisement
UsernamePublicRestriction

Register

PS072244

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel